Advisory Services Network, LLC Editas Medicine, Inc. Transaction History

Advisory Services Network, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$6.25 - $11.11 $17,181 - $30,541	2,749 New	2,749 $27,000
Q1 2023 May 17, 2023	BUY	$7.03 - $11.53 $1,406 - $2,306	200 Added 392.16%	251 $1,000
Q4 2022 Feb 13, 2023	BUY	$8.32 - $13.21 $424 - $673	51 New	51 $0
Q3 2021 Nov 05, 2021	SELL	$39.27 - $72.94 $22,266 - $41,356	-567 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$31.29 - $56.64 $17,741 - $32,114	567 New	567 $32,000
Q1 2021 May 24, 2021	SELL	$39.71 - $90.58 $34,905 - $79,619	-879 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$27.07 - $84.35 $10,557 - $32,896	390 Added 79.75%	879 $62,000
Q3 2020 Nov 16, 2020	BUY	$28.06 - $37.16 $13,721 - $18,171	489 New	489 $14,000
Q2 2020 Aug 10, 2020	SELL	$18.5 - $34.34 $2,812 - $5,219	-152 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$20.48 - $27.76 $2,293 - $3,109	112 Added 280.0%	152 $0
Q2 2018 Jul 27, 2018	SELL	$31.4 - $41.01 $14,601 - $19,069	-465 Reduced 92.08%	40 $1,000
Q1 2018 Apr 23, 2018	BUY	$29.84 - $44.08 $15,069 - $22,260	505 New	505 $0

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

Stay updated on Advisory Services Network, LLC with notifications on news.